![](/img/cover-not-exists.png)
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation
Okabe, Seiichi, Tauchi, Tetsuzo, Tanaka, Yuko, Kitahara, Toshihiko, Kimura, Shinya, Maekawa, Taira, Ohyashiki, KazumaVolume:
15
Language:
english
Journal:
Cancer Biology & Therapy
DOI:
10.4161/cbt.26725
Date:
February, 2014
File:
PDF, 2.89 MB
english, 2014